Stock Quote

BioSpecifics Technologies Corp. Announces Additional Sales of Stock in Private Placement Offering

Jun 10, 2008

BioSpecifics Technologies Corp. (OTC BB BSTC.OB-News) today announced that it sold an aggregate of 100,000 unregistered shares of its common stock priced at $15 per share for aggregate proceeds to BioSpecifics of $1,500,000. The shares were purchased by certain private investors on June 9, 2008. The shares were sold in a company managed PIPE transaction at a premium over the market price.

BioSpecifics Technologies Corp. is a biopharmaceutical company that has developed and licensed injectable collagenase for three clinical indications. It has a development and licensing agreement with Auxilium Pharmaceuticals, Inc. for clinical indications in Dupuytren's disease, Peyronie's disease and frozen shoulder (adhesive capsulitis).

                     BioSpecifics' main website is at

           its Dupuytren's Disease patient discussion forum at

          and its Peyronie's Disease patient discussion forum at

SOURCE: BioSpecifics Technologies Corp.

CONTACT: Thomas L. Wegman, President of BioSpecifics Technologies Corp.,

Web site: